Benzinga.com1d
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...
MassDevice1d
Boston Scientific Watchman FLX demonstrates superiority to anticoagulants in study
Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.
BioWorld9h
No magic with Abbott’s Amulet compared to Watchman
Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...
Pharmabiz21h
Boston Scientific WATCHMAN FLX LAAC device demonstrates superior bleeding risk reduction to OAC following a cardiac ablation in OPTION clinical trial
Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...
Edhat2d
Cottage Heart & Vascular Center Implants 1,000th WATCHMAN Device for Treatment of Atrial Fibrillation
The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...
TCTMD1d
OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain
Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.
FierceBiotech17h
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...